Professor, Clinical Research Division, Fred Hutch, Clinical Director, Genitourinary Cancers Program, Fred Hutch
Panelists discuss how androgen deprivation therapy (ADT) monotherapy is no longer acceptable for metastatic castration-sensitive prostate cancer (mCSPC), emphasizing that combination therapy with androgen receptor (AR) pathway inhibitors or chemotherapy plus universal germline testing should be the new standard of care.
Panelists discuss how the ARANOTE trial’s subgroup analysis of 65 Black patients (primarily from Brazil and South Africa) demonstrated consistent treatment benefits and highlights the importance of diversity in clinical trials to address health care disparities and potential biological differences across populations.
Panelists discuss how the ARANOTE trial’s progression-free survival benefits with darolutamide inform treatment selection between doublet and triplet approaches, emphasizing personalized decision-making based on tumor burden, patient performance status, and the “first shot, best shot” treatment philosophy.
Panelists discuss how the ARANOTE trial’s quality-of-life data and the ARCHES trial’s 5-year follow-up demonstrate sustained benefits of doublet therapy, with enzalutamide plus ADT showing a 3-year overall survival improvement in high-volume patients.
Panelists discuss how emerging trials like AMPLITUDE (PARP inhibitors for BRCA mutations), PSMA-ADDITION (radioligand therapy), and CAPITELLO (AKT inhibitors for PTEN deficiency) are moving the field toward increasingly complex, biomarker-driven treatment selection.
Panelists discuss how the ARASENSE and PEACE-1 phase 3 trials demonstrated the efficacy of triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and novel antiandrogens, while addressing the ongoing underutilization of intensified treatment approaches.
Panelists discuss how medical comorbidities, physiologic vs chronologic age, drug interactions, and performance status influence the choice between doublet and triplet therapy regimens.
Panelists discuss how clinical factors, including disease characteristics (Gleason score, volume, metastatic sites), patient factors (performance status, comorbidities, symptoms), and emerging genomic biomarkers, guide treatment intensification decisions in metastatic castration-sensitive prostate cancer.
Petros Grivas, MD, PhD, details questions and considerations for integrating perioperative durvalumab plus neoadjuvant chemotherapy into MIBC management.
Drs. Grivas and Park discuss developments in bladder cancer research, including the potential of HER2-targeted therapies and PD-1/PD-L1 inhibitors in the neoadjuvant setting.
Drs Park, Grivas, and Raychaudhuri discuss a trial of neoadjuvant aMVAC plus pembrolizumab in patients with non-urothelial muscle-invasive bladder cancer.
Panelists discuss how the CONTACT-02 trial highlights the potential of cabozantinib combined with atezolizumab in improving treatment outcomes for patients with advanced cancer.
Panelists discuss how the SPLASH trial investigating 177Lu-PNT2002 demonstrates promising efficacy in treating advanced cancer through targeted radionuclide therapy.
Panelists discuss how recent advancements in targeted therapies and a multidisciplinary approach can significantly enhance the management and care of patients with metastatic prostate cancer.
Panelists discuss how the PEACE-3 trial explores the efficacy of combining radium-223 with enzalutamide in advanced prostate cancer, highlighting its potential to enhance therapeutic outcomes and survival rates.
Panelists discuss how the ARANOTE trial exploring darolutamide in combination with androgen deprivation therapy shows potential benefits in managing advanced prostate cancer.
Panelists discuss how somatic genetic testing is essential for identifying actionable mutations in prostate cancer, guiding targeted therapies, and improving treatment outcomes for patients.
Panelists discuss how the PEACE-3 trial explores the efficacy of combining radium-223 with enzalutamide in advanced prostate cancer, highlighting its potential to enhance therapeutic outcomes and survival rates.
Panelists discuss how genetic testing for germline mutations is becoming increasingly crucial in the management of prostate cancer, enabling personalized treatment approaches and informing patient care decisions.
Panelists discuss how recent data on androgen receptor pathway inhibitor–based combination regimens highlight their potential to enhance treatment outcomes for advanced prostate cancer, underscoring the importance of integrating these findings into clinical practice.
Panelists discuss the current treatment landscape for metastatic castration-sensitive prostate cancer (mHSPC), exploring main therapeutic approaches, the role of androgen deprivation monotherapy, the timing for adding chemotherapy and ARPIs, and strategies for sequencing or combining these modalities in clinical practice.
Panelists discuss how advancements in biomarker and genetic testing, along with updated treatment guidelines, are transforming the diagnosis and management of prostate cancer, emphasizing the importance of personalized approaches in optimizing patient outcomes.
Drs Park and Grivas discuss bladder cancer treatment updates, including results from the SunRISe-1 trial of TAR-200 plus cetrelimab in NMIBC.
Petros Grivas, MD, PhD, and Chandler H. Park, MD, FACP, discuss key updates in genitourinary cancer on OncLive News Network: On Location.
OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Petros Grivas, MD, PhD, discusses frontline treatment options for patients with metastatic renal cell carcinoma.
Petros Grivas, MD, PhD, discusses potential future directions for adjuvant therapies in patients with resected renal cell carcinoma.
Petros Grivas, MD, PhD, discusses 2023 updates regarding the treatment of patients with metastatic/unresectable urothelial carcinoma.
Petros Grivas, MD, PhD, discusses outcomes associated with the phase 3 CheckMate 901 trial in metastatic or unresectable urothelial carcinoma.
Closing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.
